Bionet (1784) - Total Liabilities
Based on the latest financial reports, Bionet (1784) has total liabilities worth NT$879.32 Million TWD (≈ $27.70 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Bionet liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Bionet - Total Liabilities Trend (2017–2025)
This chart illustrates how Bionet's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Bionet balance sheet assets.
Bionet Competitors by Total Liabilities
The table below lists competitors of Bionet ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
GKW Limited
NSE:GKWLIMITED
|
India | Rs6.11 Billion |
|
Sound Financial Bancorp Inc
NASDAQ:SFBC
|
USA | $1.00 Billion |
|
Mobile Infrastructure Corporation
NASDAQ:BEEP
|
USA | $212.71 Million |
|
Tsang Yow Industrial Co Ltd
TW:1568
|
Taiwan | NT$353.63 Million |
|
Tainergy Tech Co Ltd
TW:4934
|
Taiwan | NT$640.67 Million |
|
Scandinavian Astor Group AB
ST:ASTOR
|
Sweden | Skr411.74 Million |
|
Kingwaytek Technology Co Ltd
TWO:6516
|
Taiwan | NT$261.79 Million |
|
SkyWorld Development Berhad
KLSE:5315
|
Malaysia | RM1.23 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Bionet's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 1784 net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.72 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bionet's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bionet (2017–2025)
The table below shows the annual total liabilities of Bionet from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | NT$822.58 Million ≈ $25.92 Million |
+8.18% |
| 2024-12-31 | NT$760.40 Million ≈ $23.96 Million |
+21.38% |
| 2023-12-31 | NT$626.47 Million ≈ $19.74 Million |
+21.89% |
| 2022-12-31 | NT$513.97 Million ≈ $16.19 Million |
+9.78% |
| 2021-12-31 | NT$468.19 Million ≈ $14.75 Million |
+5.11% |
| 2020-12-31 | NT$445.44 Million ≈ $14.03 Million |
-1.86% |
| 2019-12-31 | NT$453.87 Million ≈ $14.30 Million |
+2.43% |
| 2018-12-31 | NT$443.09 Million ≈ $13.96 Million |
-2.26% |
| 2017-12-31 | NT$453.33 Million ≈ $14.28 Million |
-- |
About Bionet
BIONET Corp. engages in cell therapy, regenerative medicine, medical big data, gene testing, and sales of biological and scientific information hardware and software business in Taiwan and internationally. The company offers stem cell banking services, such as stem cell storage, mesenchymal stem cell storage, dental stem cell storage, adipose stem cell, and PBSC and immune cells, as well as skin … Read more